Appia Bio is an early-stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).
B2B
26 to 50
Series A
$52 M
Scaling Up
2020
Life Sciences Tools & Services
Healthcare
Biotechnology
N/A
N/A
Service
Yes
Active
Machine Learning
N/A
Software
N/A
3
1
$52M
Company was founded 2020 and it took almost 1 year (May 2021) to raise first external round
Investors
Interested in researching Appia Bio?
We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Appia Bio
Potential Customers
Interested in what they do or partnership?
Learn more about how they work